XML 78 R40.htm IDEA: XBRL DOCUMENT v3.19.3

Other assets impairments, restructuring and other items (Tables)

9 Months Ended

Sep. 30, 2019

Schedule of Other Assets Impairments, Restructuring and Other Items

		Three months ended								Nine months ended
		September 30,								September 30,
		2019				2018				2019				2018
		(U.S. $ in millions)
Impairments of long-lived tangible assets(1)		$	28			$	2			$	96			$	255
Contingent consideration			51				29				4				84
Restructuring			61				88				140				442
Other			21				20				24				53
Total		$	160			$	139			$	263			$	834

(1) Including impairments related to exit and disposal activities

Impairments

Impairments of long-lived tangible assets for the three months ended September 30, 2019 and 2018 were $28 million and $2 million, respectively.

Impairments of long-lived tangible assets for the nine months ended September 30, 2019 and 2018 were $96 million and $255 million, respectively.

Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans as a result of its plant rationalization plan.

Contingent consideration

In the three months ended September 30, 2019, Teva recorded an expense of $51 million for contingent consideration, compared to an expense of $29 million in the three months ended September 30, 2018. The expenses in the third quarter of 2019 were mainly related to a change in the estimated future royalty payments from Eagle Pharmaceuticals, Inc. (“Eagle”) in connection with bendamustine sales.

In the nine months ended September 30, 2019, Teva recorded an expense of $4 million for contingent consideration, compared to an expense of $84 million in the nine months ended September 30, 2018. The expense in the first nine months of 2019 were mainly related to a change in the estimated future royalty payments from Eagle in connection with bendamustine sales and an increase in the expected future royalty payments to Eagle due to the orphan drug status granted to BENDEKA®, offset by the change in the future royalty payments in connection with lenalidomide (generic equivalent of Revlimid®), which was part of the Actavis Generics acquisition.

Summary of Restructuring Plan Including Costs Related to Exit and Disposal

The following tables provide the components of costs associated with Teva’s restructuring plan, including other costs associated with Teva’s restructuring plan and recorded under different items:

		Three months ended September 30,
		2019				2018
		(U.S. $ in millions)
Restructuring
Employee termination		$	49			$	62
Other			11				26
Total		$	61			$	88
		Nine months ended  September 30,
		2019				2018
		(U.S. $ in millions)
Restructuring
Employee termination		$	105			$	380
Other			34				62
Total		$	140			$	442

Summary of Restructuring Accruals

The following table provides the components of and changes in the Company’s restructuring accruals:

		Employee termination costs				Other				Total
		(U.S. $ in millions )
Balance as of January 1, 2019		$	(204	)		$	(29	)		$	(233	)
Provision			(105	)			(34	)			(140	)
Utilization and other*			108				56				164
Balance as of September 30, 2019		$	(201	)		$	(7	)		$	(208	)

* Includes adjustments for foreign currency translation.

X

- Definition

Schedule of Restructuring Charges [Table Text Block]

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfRestructuringChargesTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

+ Details

Name:	us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(2))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

+ Details

Name:	us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration